Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
wb0S7PPcBzmssvxW
